Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13606968 | 0.87 | PNP (0.46) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL13606971 | 0.81 | PNP (0.63) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL24024495 | 0.78 | LMNA (0.43) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL13606967 | 0.78 | PNP (0.48) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL6839692 | 0.71 | LMNA (0.63) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL24024511 | 0.71 | LMNA (0.54) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL7377274 | 0.71 | LMNA (0.63) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL13058163 | 0.71 | LMNA (0.63) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL24024691 | 0.71 | LMNA (0.63) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL12879146 | 0.71 | LMNA (0.54) | PNPLMNASMN1; SMN2ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638496-B2 | Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638496-B2 | Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090176721-A1 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176721-A1 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176721-A1 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE | NT5C2, PNP, SLC29A1 | PNP 2/4885LMNA 3406/4885SMN1; SMN2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.